Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 901 to 925 of 1141 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
241 increased gene expression (GO:0010467) low-density lipoprotein receptor (PR:000009744) 466: Up Regulation, LDLR (low density lipoprotein receptor)
240 increased fatty acid transport (GO:0015908) fatty acid (CHEBI:35366) 465: Increased, Fatty acid influx
239 decreased gene expression (GO:0010467) phosphoenolpyruvate carboxykinase, cytosolic [GTP] (PR:000012416) 216: Decreased, PCK1 expression (control point for glycolysis/gluconeogenesis pathway)
238 decreased secretion (GO:0046903) very-low-density lipoprotein (CHEBI:39027) 450: Decrease, Very low-density lipoprotein export capacity
237 abnormal abnormal neuron morphology (MP:0002882) 851: Decrease of GABAergic interneurons
236 decreased iodide transport (GO:0015705) iodide (CHEBI:16382)
235 decreased sodium:iodide symporter activity (GO:0008507) sodium/iodide cotransporter (PR:000015171) 424: Inhibition, Na+/I- symporter (NIS)
234 increased Nephropathy (HP:0000112) 422: Increased, nephropathy
233 increased hemorrhage (MP:0001914)
232 functional change glomerular basement membrane (UBERON:0005777) 421: Increased, glomerular rupture and renal hemorrhaging
231 abnormal sex ratio (MESH:D012744) 417: skewed, sex ratio
230 increased hormone biosynthetic process (GO:0042446) Luteinizing hormone (CHEBI:81568) 414: Increase, Luteinizing hormone (LH)
229 increased ionotropic glutamate receptor activity (GO:0004970) ionotropic glutamate receptor complex (GO:0008328) 875: Binding of agonist, Ionotropic glutamate receptors
228 functional change DNA repair (GO:0006281) Nuclear deoxyribonucleic acid (FMA:67194) 493: Increased, Insufficient repair or mis-repair of pro-mutagenic DNA adducts
227 increased hepatocyte proliferation (GO:0072574) hepatocyte (CL:0000182)
226 increased mutation (MESH:D009154) cellular tumor antigen p53 (PR:000003035) 376: Increased, Induced Mutations in Critical Genes
225 increased metabolic process (GO:0008152) 409: Metabolism of AFB1, Production of Reactive Electrophiles
224 abnormal DNA alkylation (GO:0006305) Nuclear deoxyribonucleic acid (FMA:67194) 373: Formation, Pro-mutagenic DNA Adducts
223 morphological change anatomical structure morphogenesis (GO:0009653) 1001: Increased, Developmental Defects
222 abnormal capillary plexus (UBERON:0035753) 298: Insufficiency, Vascular
221 decreased blood circulation (GO:0008015) blood (UBERON:0000178) 298: Insufficiency, Vascular
220 abnormal endothelium development (GO:0003158) 110: Impairment, Endothelial network
219 decreased angiogenesis (GO:0001525) 28: Reduction, Angiogenesis
218 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 1 (PR:000007563) 305: Inhibition, VegfR2
217 decreased vascular endothelial growth factor receptor 2 binding (GO:0043184) vascular endothelial growth factor receptor 2 (PR:000002112) 305: Inhibition, VegfR2